CAH Cardinal Health, Inc. Common Stock
关于 Cardinal Health, Inc. Common Stock 公司概况（来自维基百科）
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
阅读更多
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
History
Founded in 1971 as Cardinal Foods by Robert D. Walter, the company was initially a food wholesaler. After acquiring the Bailey Drug Company in 1979, it began whole selling drugs. The company went public on the NASDAQ stock exchange in 1983.
In 1988, Walter sold Cardinal Health's food operations to Roundy's. From 1991 to 1996, the company's sales grew from $1.2 billion to $8.9 billion. The company changed its name to Cardinal Health in 1994, and became the third-largest pharmaceutical wholesaler in the United States.
2000–2019
R. Kerry Clark, a former executive and vice chairman at Procter & Gamble, was appointed president and CEO in April 2006, with Robert D. Walter retaining Chairmanship of the board. In September 2008, the company announced Clark and Walter would retire and George S. Barrett would become the chairman and CEO.
In 2009, Cardinal Health completed the spin-off of its clinical and medical products businesses into an independent medical technology company called CareFusion with David Schlotterbeck as CEO. Cardinal Health is now traded on the NYSE under symbol CAH.
In December 2013, it was announced that Cardinal Health would partner with CVS Caremark to form a generic drug sourcing operation in the United States. The venture was named Red Oak Sourcing and began operations in July 2014.
Between 2014 and 2016, Cardinal, alongside McKesson Corporation, and AmerisourceBergen, spent $13 million lobbying Congress to pass Congressman Tom Marino's "Ensuring Patient Access and Effective Drug Enforcement Act". The bill, which increases the burden of proof enforcers need to show against drug distributors, was signed into law by President Barack Obama in April 2016.
In January 2018, Michael Kaufmann assumed the role of CEO after serving as CFO of the company.
Opioid lawsuits
In 2019, Cardinal was one of several drug distributors named in lawsuits related to the opioid crisis in the US. In July 2021, Cardinal Health and other pharmaceutical companies agreed to participate in a $26 billion settlement. Cardinal will pay $6.4 billion over 18 years.
In May 2020, Oklahoma Attorney General Mike Hunter sued Cardinal Health in Bryan County District Court, Oklahoma. The lawsuit alleged that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against AmerisourceBergen and McKesson, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets."
2020–present
As of August 2021, it is ranked 14 on the Fortune 500 list with FY2020 annual revenue of $152.9 billion. The firm employs 57,000 people worldwide.
Acquisitions
In 1995, Medicine Shoppe International, the country's largest franchiser of retail pharmacies, was acquired. The merger represented the first non-distribution acquisition by Cardinal Health.
In 1996, Cardinal Health acquired Pyxis Corporation, a company that developed automated pill dispensers for hospitals, for $867 million.
In 1997, Cardinal Health planned to purchase Bergen Brunswig Corp., to which McKesson Corporation responded with a bid to purchase Amerisource. Instead, Amerisource and Bergen merged into AmerisourceBergen. Later that year, Cardinal Health completed the acquisition of Owen Healthcare, the second-largest provider of pharmacy management services in the U.S. at the time.
In 1999, the firm acquired the Chicago-based medical products manufacturer and distributor, Allegiance Healthcare (formerly a division of Baxter Healthcare). In 2001, the company acquired Bindley Western Industries, a wholesale distributor of pharmaceuticals based in Indianapolis.
In April 2006, Cardinal Health purchased Niagara Falls-based ParMed Pharmaceuticals for $40.1 million. In June 2007, the firm announced the completion of a tender offer for VIASYS Healthcare.
In June 2010, Cardinal Health announced plans to purchase Healthcare Solutions Holding, a specialty pharmaceutical services company, for $517 million. In December 2010, the company acquired Kinray, an independent pharmaceutical wholesaler, increasing Cardinal Health's presence in the independent pharmacy market by 40 percent. From 2010 to 2014, Cardinal Health acquired 18 companies including Yong Yu, a Chinese drug distributor. Cardinal sold Yong Yu in 2017 to Shanghai Pharmaceuticals Holding Co. Ltd. for $1.2 billion.
On March 18, 2013, Cardinal Health acquired the Twinsburg, Ohio-based privately held medical supply distributor AssuraMed, and with it its subsidiaries including Edgepark Medical Supplies, for $2.7 billion. AssuraMed was backed by private equity firms Clayton, Dubilier & Rice and Goldman Sachs Alternatives.
In July 2014, Cardinal Health and CVS formed Red Oak Sourcing, the largest generic drug sourcing operation in the United States. The companies started buying generic drugs around the world to sell in U.S. markets.
In March 2015, Cardinal Health signed an agreement to acquire Johnson & Johnson's Cordis (medical) division, a cardiology and endovascular device manufacturer, for $1.94 billion. The acquisition was completed on October 4, 2015. Cardinal sold the division in August 2021 to Hellman & Friedman, a private equity firm, for $1 billion.
In April 2017, Cardinal Health announced the plan to acquire the patient product portfolio from Medtronic for $6.1 billion. The acquisition was completed on July 30, 2017.
In November 2024, Cardinal Health announced the plan to acquire Advanced Diabetes Supply Group (ADSG), a leading national direct-to-patient provider of diabetes medical supplies, for about $1.1 billion with plans to merge the company into its at-Home Solutions business. The at-Home Solutions business includes Edgepark Medical Supplies of Twinsburg, Ohio and United States Medical Supply (US MED) of Doral, Florida. The acquisition was complete by April 2024.
In August 2025, Cardinal Health announced that it would acquire a 75% stake in Solaris Health, the largest urology management services organization (MSO) in the United States, for $1.9 billion in cash.
In July 2026, Cardinal Health agreed to acquire AdaptHealth's diabetes health business and medical-supply provider Strive Medical in separate transactions worth approximately US$360 million in total. The acquisitions were intended to expand its at-Home Solutions business in diabetes and urological care.
Controversy
Role in the Opioid epidemic
Multiple legal settlements have demonstrated Cardinal Health's role in the US Opioid epidemic, though the company never admitted wrongdoing:
December 2016: Cardinal Health settled for $44 million for violations of the Controlled Substances Act brought in allegations from United States Attorneys in districts from Maryland, New York, Florida and Washington.
July 2021: Cardinal Health agreed to pay $6.4 billion to settle thousands of US lawsuits. They were one of four companies to pay $26 billion, including Johnson & Johnson, AmerisourceBergen and McKesson.
May 2022: Settled a derivative suit on behalf of shareholders for $124 million.
August 2024: Settlement with various health plans including insurers and third-party payers for $92.7 million.
August 2024: Settlement with the City of Baltimore for $152.5 million.
Restatements
In September 2004, Cardinal Health announced plans to restate past results for fiscal 2001, 2002, 2003, and the first three quarters of 2004 downward, after an accounting review and an ongoing federal investigation. In 2005, in connection with the Audit Committee's conclusions reached in September and October 2004, the company made certain reclassification and restatement adjustments to its fiscal 2004 and prior historical consolidated financial statements. According to The Wall Street Journal, "Analysts called the restatement decision troubling, yet limited in scope."
FDA action
In August 2006, Cardinal Health ceased production of its Alaris SE infusion pump after approximately 1300 units were seized by the United States Food and Drug Administration (FDA). In February 2007, Cardinal Health signed a consent decree with the FDA which promised procedures to guarantee the safety of the Alaris SE. After FDA inspections, Cardinal Health entered into a further consent agreement with the FDA in 2009.
DEA investigation into Oxycodone diversion
In 2008, Cardinal Health agreed to pay $34 million in civil penalties to settle DEA allegations that it failed to report suspicious orders of hydrocodone. The fine followed a 10-month DEA suspension of a Lakeland, Florida distribution facility and two others in New Jersey and Washington. On February 2, 2012, the Drug Enforcement Administration again suspended the license of the firm's Lakeland distribution center to distribute controlled substances on charges that it had allowed four Florida pharmacies to purchase excessive amounts of controlled substances, in particular oxycodone.
Cardinal Health obtained a restraining order against the suspension, but the suspension was upheld on February 29 by a Federal district court because the court agreed with the DEA that Cardinal Health's activities represented an "imminent danger to the public." The company stated that it blocked two of the pharmacies, (Brooks Pharmacy in Bonita Springs, Florida, and Gulf Coast Medical in Panama City, Florida), and notified the corporate owners of the two pharmacies that were part of national chains, two CVS stores in Sanford, Florida.
In February 2012, Joseph Rannazzisi, chief of the Drug Enforcement Administration’s Office of Diversion Control, issued immediate suspension orders against Cardinal's supply of oxycodone to suspected pill mills. These orders were filed after Deputy Attorney General James M. Cole met with Rannazzisi to ask if he had met with Cardinal about the investigation. Cole stated that he believed “it made good sense to listen to what Cardinal had to say” regarding the investigation. That year, Cardinal and the DEA reached a settlement that suspended Cardinal's facility in Lakeland, Florida from selling pain killers or other drugs for two years. In 2016, Cardinal was fined $44 million for after the investigation concluded.
In January 2022, Cardinal Health, Johnson & Johnson, McKesson, and AmerisourceBergen agreed to pay $26 billion to settle with all but five of the states suing them. Had the states gone to court, the companies could have faced up to $95 billion in penalties.
Finances
Annual financial statistics are displayed below:
Cardinal Health Foundation
The Cardinal Health Foundation is the charitable arm of Cardinal Health. The company makes annual product donations of over $9 million through international relief organizations and provides up to $1,000 in matching funds for every Cardinal Health employee that makes a charitable donation. In 2008, the foundation established its E3 Grant Program. Over the past seven years, the Foundation has invested more than $7.15 million in funding to 241 hospitals, health systems or other health-related organizations.
Cardinal Health also supports organizations such as Ronald McDonald House Charities, and was named Benefactor of the Year at the 2011 Corporate Caring Awards. In 2015, the foundation contributed $3 million to the Solutions for Patient Safety project, which has raised over $11 million nationally for efforts to improve safety initiatives in children's hospitals.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
CAH 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
CAH 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
股息 收益率、派息率、股息历史、5年CAGR
| 除息日 | 金额 |
|---|---|
| 2026年7月1日 | $0.5160 |
| 2026年4月1日 | $0.5110 |
| 2026年1月2日 | $0.5110 |
| 2025年10月1日 | $0.5110 |
| 2025年7月1日 | $0.5110 |
| 2025年4月1日 | $0.5060 |
| 2025年1月2日 | $0.5060 |
| 2024年10月1日 | $0.5060 |
| 2024年7月1日 | $0.5060 |
| 2024年3月28日 | $0.5010 |
| 2023年12月29日 | $0.5010 |
| 2023年10月2日 | $0.5010 |
| 2023年6月30日 | $0.5010 |
| 2023年3月31日 | $0.4960 |
| 2022年12月30日 | $0.4960 |
| 2022年9月30日 | $0.4960 |
| 2022年6月30日 | $0.4960 |
| 2022年3月31日 | $0.4910 |
| 2021年12月31日 | $0.4910 |
| 2021年9月30日 | $0.4910 |
CAH 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 8 34.8%
- 买入 12 52.2%
- 持有 3 13.0%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
15 位分析师 · 2026-08-14收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年12月31日 | $2.91 | $2.44 | 0.47% |
| 2026年6月30日 | $2.91 | $2.44 | 0.47% |
| 2026年3月31日 | $3.17 | $2.82 | 0.35% |
| 2025年12月31日 | $2.63 | $2.40 | 0.23% |
| 2025年9月30日 | $2.55 | $2.20 | 0.35% |
| 2025年6月30日 | $2.08 | $2.06 | 0.02% |
| 2025年3月31日 | $2.35 | $2.19 | 0.16% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| CAH | — | 32.9 | 14.2% | 0.67% | -60.5% | 3.8% |
| MCK | $242.30B | 22.5 | 12.4% | 1.2% | -224.3% | 3.6% |
| COR | $60.61B | 39.3 | 9.3% | 0.48% | 144.3% | 3.6% |
| HSIC | $8.81B | 23.3 | 4.0% | 3.0% | 12.0% | 31.1% |
| AHCO | $1.35B | -19.2 | -0.49% | -2.2% | -4.6% | — |
| ACH | — | — | — | — | — | — |
| MEDS | — | — | — | — | — | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 15
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Cost of Revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B | $123.43B | $115.00B | $96.82B | |
| Gross Profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B | $6.54B | $5.71B | |
| SG&A Expense | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B | $3.77B | $3.65B | $3.24B | |
| Operating Income | $2.61B | $2.27B | $1.24B | $752M | $-607M | $472M | $-4.10B | $2.06B | $126M | $2.12B | $2.46B | $2.16B | |
| Interest Expense | $348M | $215M | $51M | $84M | $147M | $180M | $238M | $294M | $329M | $201M | $178M | $141M | |
| Other Non-op | $31M | $41M | $9M | $-5M | $-22M | $47M | $1M | $-15M | $-23M | $5M | $-5M | $7M | |
| Pretax Income | $2.17B | $2.10B | $1.20B | $663M | $-784M | $323M | $-3.77B | $1.75B | $-228M | $1.92B | $2.28B | $1.97B | |
| Income Tax | $469M | $532M | $348M | $332M | $153M | $-289M | $-79M | $386M | $-487M | $630M | $845M | $755M | |
| Net Income | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| EPS (Basic) | $7.27 | $6.48 | $3.48 | $1.27 | $-3.37 | $2.09 | $-12.61 | $4.55 | $0.82 | $4.06 | $4.36 | $3.66 | |
| EPS (Diluted) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 | |
| Shares (Basic) | 236,000,000 | 241,000,000 | 245,000,000 | 261,000,000 | 279,000,000 | 292,000,000 | 293,000,000 | 300,000,000 | 313,000,000 | 317,000,000 | 327,000,000 | 332,000,000 | |
| Shares (Diluted) | 237,000,000 | 242,000,000 | 247,000,000 | 262,000,000 | 279,000,000 | 294,000,000 | 293,000,000 | 301,000,000 | 315,000,000 | 320,000,000 | 330,000,000 | 335,000,000 | |
| EBITDA | $3.57B | $3.06B | $1.95B | $1.42B | $96M | $1.25B | $-3.19B | $3.06B | $1.16B | $2.84B | $3.10B | $2.61B |
资产负债表 25
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.72B | $3.41B | $2.77B | $2.53B | $1.76B | $6.88B | $2.36B | $4.62B | |
| Short-term Investments | · | · | $200M | · | · | · | · | · | · | $65M | $113M | $91M | |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B | $9.10B | $8.26B | $8.45B | $7.80B | $8.05B | $7.41B | $6.52B | |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B | $14.59B | $13.20B | $12.82B | $12.31B | $11.30B | $10.62B | $9.21B | |
| Other Current Assets | $2.76B | $2.41B | $2.66B | $2.29B | $2.02B | $2.84B | $1.71B | $1.95B | $1.93B | $2.12B | $1.58B | $1.40B | |
| Current Assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B | $31.05B | $25.94B | $25.75B | $24.55B | $28.34B | $21.96B | $21.75B | |
| PP&E (Net) | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B | $2.36B | $2.37B | $2.36B | $2.49B | $1.88B | $1.80B | $1.51B | |
| PP&E (Gross) | $7.97B | $7.52B | $6.70B | $6.31B | $5.88B | $5.59B | $5.33B | $5.17B | $5.26B | $4.63B | $4.48B | $4.03B | |
| Accum. Depreciation | $4.93B | $4.66B | $4.17B | $3.85B | $3.52B | $3.23B | $2.96B | $2.81B | $2.77B | $2.75B | $2.68B | $2.53B | |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B | $7.99B | $8.36B | $8.38B | $8.32B | $7.22B | $7.17B | $5.07B | |
| Intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B | $2.10B | $2.92B | $3.43B | $3.91B | $1.99B | $1.99B | $948M | |
| Other Non-current Assets | $1.88B | $1.71B | $1.26B | $1.07B | $953M | $951M | $1.19B | $1.05B | $682M | $681M | $944M | $866M | |
| Total Assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B | |
| Accounts Payable | $38.28B | $34.71B | $31.76B | $29.93B | $27.13B | $23.70B | $21.37B | $21.54B | $19.68B | $17.91B | $17.31B | $14.37B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | $0 | |
| Current Liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B | $27.62B | $23.61B | $24.11B | $22.89B | $21.22B | $19.70B | $17.24B | |
| Capital Leases | $861M | $654M | $400M | $375M | $388M | $374M | $341M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $1.75B | $1.81B | $1.95B | $1.70B | $328M | |
| Total Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | · | |
| Common Stock | $2.89B | $2.96B | $2.92B | $2.75B | $2.81B | $2.81B | $2.79B | $2.76B | $2.73B | $2.70B | $3.01B | $3.00B | |
| Retained Earnings | $2.01B | $783M | $-286M | $-642M | $-280M | $1.21B | $1.17B | $5.43B | $4.64B | $4.97B | $6.42B | $5.52B | |
| Treasury Stock | $7.61B | $6.37B | $5.68B | $4.91B | $3.13B | $2.19B | $2.07B | $1.79B | $1.22B | $731M | $2.76B | $2.25B | |
| AOCI | $-165M | $-155M | $-167M | $-151M | $-114M | $-34M | $-104M | $-79M | $-92M | $-125M | $-116M | $-23M | |
| Stockholders' Equity | $-2.88B | $-2.78B | $-3.21B | $-2.96B | $-709M | $1.79B | $1.79B | $6.33B | $6.06B | $6.81B | $6.55B | $6.26B | |
| Liabilities + Equity | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B |
现金流 19
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $956M | $790M | $710M | $692M | $692M | $783M | $913M | $1.00B | $1.03B | $717M | $641M | $451M | |
| Stock-based Comp | $367M | $244M | $121M | $96M | $81M | $89M | $90M | $82M | $85M | $96M | $111M | $110M | |
| Deferred Tax | $91M | $243M | $-104M | $-40M | $14M | $496M | $-961M | $-83M | $-1.01B | $291M | $87M | $219M | |
| Amort. of Intangibles | $361M | $303M | $264M | $281M | $311M | $428M | $512M | $531M | $574M | $395M | $355M | $191M | |
| Restructuring | $106M | $88M | $175M | $95M | $101M | $114M | $122M | $125M | $176M | $56M | $25M | $44M | |
| Other Non-cash | $2.05B | $-441M | $2.18B | $1.82B | $3.27B | $450M | $5.61B | $360M | $2.41B | · | $705M | $545M | |
| Operating Cash Flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B | $2.43B | $1.96B | $2.72B | $2.77B | $1.18B | $2.97B | $2.54B | |
| CapEx | $649M | $547M | $511M | $481M | $387M | $400M | $375M | $328M | $384M | $387M | $465M | $300M | |
| Investing Cash Flow | $-2.58B | $-5.59B | $-1.85B | $-454M | $567M | $-378M | $493M | $338M | $-5.61B | $-405M | $-4.08B | $-849M | |
| Debt Issued | $1.00B | $2.90B | $1.14B | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $347M | $2.46B | $357M | $-579M | $-885M | $-570M | $-1.40B | $-1.10B | $-954M | $-310M | $-6M | $-1.22B | |
| Stock Repurchased | $1.36B | $765M | $750M | $2.00B | $1.00B | $200M | $350M | $600M | $550M | $600M | $651M | $1.04B | |
| Net Stock Activity | $-1.36B | $-765M | $-750M | $-2.00B | $-1.00B | $-200M | $-350M | $-600M | $-550M | $-600M | $-651M | $-1.04B | |
| Dividends Paid | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M | |
| Financing Cash Flow | $-1.60B | $1.94B | $-847M | $-3.05B | $-2.46B | $-1.32B | $-2.20B | $-2.29B | $-2.28B | $3.75B | $-1.14B | $60M | |
| Net Change in Cash | $982M | $-1.26B | $1.06B | $-669M | $1.36B | $636M | $240M | $768M | $-5.12B | $4.52B | $-2.26B | $1.75B | |
| Taxes Paid | $338M | $444M | $191M | $156M | $-766M | $273M | $368M | $311M | $425M | $686M | $635M | $529M | |
| Free Cash Flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B | $2.03B | $1.58B | $2.39B | $2.38B | $797M | $2.51B | $2.24B | |
| Levered FCF | $4.25B | $1.69B | $3.21B | $2.32B | $2.55B | $1.69B | $1.35B | $2.16B | $2.76B | $662M | $2.39B | $2.15B |
盈利能力 8
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | 4.2% | 4.5% | 4.7% | 5.2% | 5.0% | 5.4% | 5.6% | |
| Operating Margin | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% | 0.29% | -2.7% | 1.4% | 0.09% | 1.6% | 2.0% | 2.1% | |
| Net Margin | 0.67% | 0.70% | 0.38% | 0.13% | -0.51% | 0.38% | -2.4% | 0.94% | 0.19% | · | 1.2% | 1.2% | |
| Pretax Margin | 0.86% | 0.94% | 0.53% | 0.31% | -0.42% | 0.20% | -2.5% | 1.2% | -0.17% | 1.5% | 1.9% | 1.9% | |
| EBITDA Margin | 1.4% | 1.4% | 0.86% | 0.69% | 0.05% | 0.77% | -2.1% | 2.1% | 0.85% | 2.2% | 2.5% | 2.5% | |
| ROA | 3.1% | 3.2% | 1.9% | 0.60% | -2.1% | 1.4% | -9.0% | 3.4% | 0.64% | · | 4.4% | 4.3% | |
| ROE | -60.5% | -52.1% | -27.6% | -14.7% | -172.5% | 34.1% | -91.1% | 22.0% | 4.0% | · | 22.3% | 19.2% | |
| ROIC | -71.1% | -61.1% | -27.5% | -10.5% | 101.9% | 49.9% | -224.3% | 25.4% | -2.4% | 18.6% | 23.6% | 21.3% |
流动性与偿付能力 4
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.3 | |
| Quick Ratio | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.7 | 0.5 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | 0.1 | 0.0 | · | |
| Interest Coverage | 7.5 | 10.6 | 24.4 | 7.8 | -4.0 | 2.6 | -17.2 | 7.0 | 0.4 | 10.5 | 13.8 | 15.3 |
效率 3
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 4.6 | 4.5 | 5.1 | 4.7 | 4.1 | 3.8 | 3.7 | 3.6 | 3.4 | 3.5 | 3.8 | 3.7 | |
| Inventory Turnover | 14.3 | 13.5 | 14.1 | 12.5 | 11.6 | 11.2 | 11.2 | 11.0 | 11.0 | 11.3 | 11.6 | 11.1 | |
| Receivables Turnover | 18.8 | 17.6 | 19.6 | 18.7 | 18.4 | 18.7 | 18.3 | 17.9 | 17.3 | 16.8 | 17.5 | 17.2 |
增长率 10
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 14.2% | -1.9% | 10.7% | 13.0% | 11.6% | 6.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.4% | 7.1% | 11.8% | 10.3% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.4% | 7.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 12.1% | 87.0% | 173.8% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 79.0% | · | 18.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 28.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 9.8% | 83.2% | 158.2% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 73.2% | · | 11.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | -3.0% | -2.8% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 6
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Net Income TTM | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| P/E | 32.9 | 26.0 | 28.5 | 75.1 | -15.5 | 27.4 | -4.1 | 10.4 | 60.3 | 19.3 | 18.1 | 23.1 | |
| Earnings Yield | 3.0% | 3.8% | 3.5% | 1.3% | -6.5% | 3.6% | -24.2% | 9.6% | 1.7% | 5.2% | 5.5% | 4.3% | |
| Payout Ratio | 28.6% | 31.6% | 58.6% | 201.1% | -59.9% | 93.8% | -15.4% | 42.3% | 226.9% | · | 35.9% | 37.9% | |
| Annual Payout | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M |
损益表 15
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.67B | $60.94B | $65.63B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B | $59.87B | $54.87B | $57.44B | $54.65B | $53.42B | $50.50B | $51.47B | $49.59B | |
| Cost of Revenue | $61.11B | $58.44B | $63.23B | $61.69B | $57.96B | $52.76B | $53.32B | $50.38B | $57.98B | $52.93B | $55.59B | $52.91B | $51.61B | $48.69B | $49.78B | $48.00B | |
| Gross Profit | $2.56B | $2.50B | $2.40B | $2.32B | $2.20B | $2.12B | $1.94B | $1.90B | $1.88B | $1.94B | $1.85B | $1.74B | $1.81B | $1.81B | $1.68B | $1.60B | |
| SG&A Expense | $1.62B | $1.54B | $1.50B | $1.46B | $1.48B | $1.31B | $1.31B | $1.28B | $1.28B | $1.27B | $1.27B | $1.19B | $1.23B | $1.17B | $1.18B | $1.20B | |
| Operating Income | $729M | $509M | $707M | $668M | $428M | $730M | $549M | $568M | $401M | $369M | $505M | $-32M | $162M | $604M | $-86M | $123M | |
| Interest Expense | · | · | $88M | $80M | $74M | $74M | $35M | $32M | $9M | $28M | $3M | $11M | $6M | $26M | $24M | $24M | |
| Other Non-op | $26M | $-16M | $11M | $10M | $30M | $9M | $-3M | $5M | $-1M | $1M | $10M | $-1M | $-10M | $-2M | $6M | $-3M | |
| Pretax Income | $554M | $392M | $630M | $598M | $384M | $665M | $511M | $541M | $391M | $342M | $512M | $-44M | $146M | $576M | $-104M | $96M | |
| Income Tax | $154M | $12M | $159M | $144M | $141M | $157M | $110M | $124M | $158M | $80M | $143M | $-33M | $143M | $209M | $-27M | $-3M | |
| Net Income | $398M | $399M | $467M | $450M | $239M | $506M | $400M | $416M | $235M | $261M | $368M | $-12M | $5M | $365M | $-77M | $98M | |
| EPS (Basic) | · | · | · | $1.89 | · | · | · | $1.71 | · | $1.07 | $1.50 | $-0.05 | · | $1.43 | $-0.30 | $0.36 | |
| EPS (Diluted) | · | · | · | $1.88 | · | · | · | $1.70 | · | $1.07 | $1.50 | $-0.05 | · | $1.41 | $-0.30 | $0.36 | |
| Shares (Basic) | -473,000,000 | 235,000,000 | 236,000,000 | 238,000,000 | -484,000,000 | 240,000,000 | 242,000,000 | 243,000,000 | -492,000,000 | 243,000,000 | 245,000,000 | 249,000,000 | -527,000,000 | 256,000,000 | 261,000,000 | 271,000,000 | |
| Shares (Diluted) | -475,000,000 | 236,000,000 | 237,000,000 | 239,000,000 | -487,000,000 | 241,000,000 | 243,000,000 | 245,000,000 | -493,000,000 | 245,000,000 | 246,000,000 | 249,000,000 | -530,000,000 | 258,000,000 | 261,000,000 | 273,000,000 | |
| EBITDA | · | $757M | $941M | $901M | · | $730M | $549M | $750M | · | $367M | $482M | $158M | · | $572M | $-119M | $308M |
资产负债表 21
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.94B | $2.78B | $4.59B | $3.87B | $3.33B | $3.81B | $2.87B | $5.13B | $3.72B | $4.59B | $3.85B | · | $3.99B | $3.65B | $3.49B | |
| Receivables | $13.81B | $13.65B | $13.66B | $13.77B | $13.24B | $12.67B | $12.37B | $11.78B | $12.08B | $11.57B | $11.79B | $11.27B | · | $10.99B | $11.42B | $11.04B | |
| Inventory | $17.30B | $18.01B | $20.12B | $17.56B | $16.83B | $16.16B | $16.90B | $15.62B | $14.96B | $17.28B | $18.45B | $16.99B | · | $16.62B | $17.26B | $15.89B | |
| Other Current Assets | $2.76B | $2.47B | $2.67B | $2.60B | $2.41B | $2.40B | $2.62B | $2.59B | $2.66B | $3.16B | $2.82B | $2.58B | · | $1.90B | $2.26B | $2.27B | |
| Current Assets | $38.75B | $38.06B | $39.23B | $38.54B | $36.37B | $34.59B | $35.76B | $32.91B | $34.88B | $35.73B | $37.66B | $34.69B | · | $33.50B | $34.60B | $32.70B | |
| PP&E (Net) | $3.03B | $2.93B | $2.88B | $2.83B | $2.86B | $2.66B | $2.56B | $2.54B | $2.53B | $2.47B | $2.45B | $2.44B | · | $2.36B | $2.34B | $2.34B | |
| PP&E (Gross) | $7.97B | · | · | · | $7.52B | · | · | · | $6.70B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $4.93B | · | · | · | $4.66B | · | · | · | $4.17B | · | · | · | · | · | · | · | |
| Goodwill | $11.44B | $11.41B | $11.61B | $9.71B | $9.69B | $8.91B | $5.49B | $4.72B | $4.72B | $4.79B | $4.02B | $4.03B | $4.61B | $5.00B | $4.99B | $5.67B | |
| Intangibles | $2.19B | $2.28B | $2.37B | $2.40B | $2.49B | $2.11B | $1.95B | $1.66B | $1.73B | $1.72B | $1.35B | $1.41B | · | $1.57B | $1.63B | $1.69B | |
| Other Non-current Assets | $1.88B | $2.00B | $2.00B | $1.75B | $1.71B | $1.60B | $1.25B | $1.23B | $1.26B | $1.17B | $1.10B | $1.15B | · | $951M | $927M | $985M | |
| Total Assets | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B | |
| Accounts Payable | $38.28B | $37.83B | $39.00B | $36.86B | $34.71B | $32.81B | $31.30B | $30.36B | $31.76B | $32.09B | $34.26B | $31.54B | · | $29.60B | $30.08B | $28.36B | |
| Current Liabilities | $43.90B | $41.99B | $43.31B | $40.27B | $38.90B | $36.66B | $35.22B | $34.68B | $35.64B | $36.31B | $38.29B | $35.06B | · | $32.50B | $33.21B | $31.56B | |
| Capital Leases | $861M | · | · | · | $654M | · | · | · | $400M | · | · | · | · | · | · | · | |
| Common Stock | $2.89B | $2.81B | $2.85B | $2.75B | $2.96B | $2.95B | $2.93B | $2.83B | $2.92B | $2.89B | $2.85B | $2.73B | · | $2.82B | $2.75B | $2.58B | |
| Retained Earnings | $2.01B | $1.73B | $1.46B | $1.12B | $783M | $664M | $283M | $14M | $-286M | $-289M | $-425M | $-654M | · | $-342M | $-560M | $-301M | |
| Treasury Stock | $7.61B | $7.22B | $7.03B | $6.58B | $6.37B | $6.38B | $6.03B | $5.96B | $5.68B | $5.70B | $5.72B | $5.40B | $4.91B | $4.55B | $4.25B | $3.88B | |
| AOCI | $-165M | $-161M | $-153M | $-159M | $-155M | $-176M | $-180M | $-155M | $-167M | $-160M | $-155M | $-165M | · | $-142M | $-146M | $-176M | |
| Stockholders' Equity | $-2.88B | $-2.83B | $-2.88B | $-2.88B | $-2.78B | $-2.95B | $-2.99B | $-3.28B | $-3.21B | $-3.27B | $-3.45B | $-3.49B | · | $-2.22B | $-2.21B | $-1.78B | |
| Liabilities + Equity | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B |
现金流 17
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $241M | $248M | $234M | $233M | $209M | $207M | $192M | $182M | $186M | $177M | $175M | $172M | $176M | $175M | $170M | $171M | |
| Stock-based Comp | $58M | $129M | $87M | $93M | $153M | $31M | $30M | $30M | $33M | $31M | $28M | $29M | $27M | $21M | $25M | $23M | |
| Amort. of Intangibles | $95M | $95M | $84M | $87M | $89M | $77M | $69M | $68M | $73M | $64M | $63M | $64M | $70M | $69M | $71M | $71M | |
| Restructuring | $40M | $25M | $21M | $20M | $27M | $28M | $9M | $24M | $69M | $53M | $28M | $25M | $33M | $16M | $17M | $29M | |
| Other Non-cash | · | · | · | $197M | · | · | · | $-2.27B | · | · | · | $339M | · | · | · | $-281M | |
| Operating Cash Flow | $1.69B | $1.82B | $686M | $973M | $1.52B | $2.92B | $-396M | $-1.65B | $2.08B | $-54M | $1.16B | $528M | $863M | $1.36B | $597M | $23M | |
| CapEx | $264M | $146M | $131M | $108M | $232M | $126M | $99M | $90M | $193M | $112M | $114M | $92M | $217M | $109M | $85M | $70M | |
| Investing Cash Flow | $-281M | $-181M | $-1.98B | $-142M | $-1.63B | $-2.90B | $-976M | $-88M | $166M | $-1.85B | $-105M | $-63M | $-206M | $-91M | $-87M | $-70M | |
| Debt Issued | $0 | $0 | $0 | $1.00B | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | $488M | · | · | · | $-9M | · | · | · | $-7M | · | · | · | $-7M | |
| Stock Repurchased | $350M | $250M | $383M | $375M | $0 | $375M | $15M | $375M | $0 | $0 | $250M | $500M | $500M | $250M | $250M | $1.00B | |
| Net Stock Activity | · | · | · | $-375M | · | · | · | $-375M | · | · | · | $-500M | · | · | · | $-1.00B | |
| Dividends Paid | $120M | $120M | $122M | $129M | $120M | $124M | $122M | $128M | $122M | $122M | $124M | $131M | $126M | $128M | $129M | $142M | |
| Financing Cash Flow | $-490M | $-483M | $-519M | $-110M | $663M | $-507M | $2.33B | $-540M | $-859M | $1.03B | $-353M | $-666M | $-592M | $-934M | $-362M | $-1.16B | |
| Net Change in Cash | $919M | $1.16B | $-1.82B | $719M | $548M | $-484M | $943M | $-2.27B | $1.39B | $-878M | $710M | $-206M | $58M | $336M | $162M | $-1.23B | |
| Free Cash Flow | · | · | · | $865M | · | · | · | $-1.74B | · | · | · | $453M | · | · | · | $-47M | |
| Levered FCF | · | · | · | $804M | · | · | · | $-1.76B | · | · | · | $456M | · | · | · | $-72M |
盈利能力 8
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 4.1% | 3.6% | 3.6% | · | 3.9% | 3.5% | 3.6% | · | 3.5% | 3.2% | 3.2% | · | 3.5% | 3.2% | 3.2% | |
| Operating Margin | · | 0.84% | 1.1% | 1.0% | · | 1.3% | 0.99% | 1.1% | · | 0.67% | 0.84% | -0.03% | · | 1.1% | -0.23% | 0.28% | |
| Net Margin | · | 0.65% | 0.71% | 0.70% | · | 0.92% | 0.72% | 0.80% | · | 0.47% | 0.61% | 0.01% | · | 0.68% | -0.25% | 0.22% | |
| Pretax Margin | · | 0.64% | 0.96% | 0.93% | · | 1.2% | 0.92% | 1.0% | · | 0.62% | 0.85% | -0.05% | · | 1.1% | -0.27% | 0.22% | |
| EBITDA Margin | · | 1.2% | 1.4% | 1.4% | · | 1.3% | 0.99% | 1.4% | · | 0.67% | 0.84% | 0.29% | · | 1.1% | -0.23% | 0.62% | |
| ROA | · | 0.75% | 0.89% | 0.92% | · | 1.1% | 0.85% | 0.96% | · | 0.58% | 0.78% | 0.01% | · | 0.81% | -0.29% | 0.25% | |
| ROE | · | -13.8% | -15.9% | -14.6% | · | -16.3% | -12.4% | -12.3% | · | -9.4% | -12.5% | -0.19% | · | -23.6% | 21.4% | -56.7% | |
| ROIC | · | -17.4% | -18.3% | -17.6% | · | -18.9% | -14.4% | -13.4% | · | -8.5% | -10.1% | -0.09% | · | -16.4% | 5.1% | -7.8% |
流动性与偿付能力 3
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.9 | 0.9 | 1.0 | · | 0.9 | 1.0 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | |
| Quick Ratio | · | 0.4 | 0.4 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | 8.0 | 8.3 | · | 9.9 | 15.7 | 17.8 | · | 11.1 | 60.2 | -1.0 | · | 20.4 | -4.8 | 5.5 |
效率 3
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 1.1 | 1.2 | 1.3 | · | 1.1 | 1.2 | 1.2 | · | 1.2 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | |
| Inventory Turnover | · | 3.4 | 3.4 | 3.7 | · | 3.2 | 3.0 | 3.1 | · | 3.1 | 3.1 | 3.2 | · | 3.0 | 3.1 | 3.1 | |
| Receivables Turnover | · | 4.6 | 5.0 | 5.0 | · | 4.5 | 4.6 | 4.5 | · | 4.9 | 5.0 | 4.9 | · | 4.8 | 4.9 | 4.9 |
估值 (TTM) 5
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $245.45B | $239.78B | $226.43B | · | $217.29B | $219.85B | $219.24B | · | $217.46B | $214.06B | $206.21B | · | $196.39B | $191.35B | $183.85B | |
| Net Income TTM | · | $1.82B | $1.82B | $1.77B | · | $1.58B | $1.45B | $1.03B | · | $982M | $644M | $374M | · | $-1.00B | $-1.32B | $-973M | |
| P/E | · | · | · | · | · | 32.6 | 28.0 | 26.2 | · | 28.5 | 39.4 | 61.1 | · | · | · | · | |
| Earnings Yield | · | · | · | · | · | 3.1% | 3.6% | 3.8% | · | 3.5% | 2.5% | 1.6% | · | · | · | · | |
| Payout Ratio | · | · | · | 28.7% | · | · | · | 30.8% | · | · | · | 2620.0% | · | · | · | 129.1% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | |
|---|---|---|---|---|---|
| 收入 | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B |
| 毛利率 % | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% |
| 营业利润率 % | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% |
| 净收入 | $1.71B | $1.56B | $852M | $330M | $-938M |
| 稀释后每股收益 (EPS) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 |
资产负债表
| 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | |
|---|---|---|---|---|---|
| 流动比率 | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 |
| 速动比率 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 |
现金流
| 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | |
|---|---|---|---|---|---|
| 自由现金流 | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 1620 家申报者 · $31.0B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 164 (-14 与上一季度对比) | 80 (-18 与上一季度对比) | 518 (-31 与上一季度对比) | 546 (+37 与上一季度对比) | +3.8M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3632811706 | 15292186 | 11.72% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3258822899 | 13717894 | 10.51% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $3254296668 | 13698841 | 10.50% | 股份 |
| STATE STREET CORP | $2842909265 | 11967121 | 9.17% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $1350305229 | 5709017 | 4.36% | 股份 |
| WCM INVESTMENT MANAGEMENT, LLC | $971445537 | 4112461 | 3.13% | 股份 |
| NORGES BANK | $885248810 | 3726422 | 2.86% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $499624076 | 2103149 | 1.61% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $469793667 | 1977579 | 1.52% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $315702986 | 1328940 | 1.02% | 股份 |
| VANGUARD GROUP INC | $277003725 | 1347950 | 0.89% | 股份 |
| Robeco Institutional Asset Management B.V. | $258918781 | 1089909 | 0.84% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $244584818 | 1029571 | 0.79% | 股份 |
| ENVESTNET ASSET MANAGEMENT INC | $230523823 | 970390 | 0.74% | 股份 |
| BlackRock, Inc. | $225912433 | 950970 | 0.73% | 股份 |
| Man Group plc | $220862620 | 929713 | 0.71% | 股份 |
| FMR LLC | $211855495 | 891798 | 0.68% | 股份 |
| GOLDMAN SACHS GROUP INC | $199229035 | 838647 | 0.64% | 股份 |
| ProShare Advisors LLC | $197187154 | 830052 | 0.64% | 股份 |
| NORDEA INVESTMENT MANAGEMENT AB | $192568890 | 809283 | 0.62% | 股份 |
| Legal & General Group Plc | $184918605 | 778408 | 0.60% | 股份 |
| JANE STREET GROUP, LLC | $169712864 | 714400 | 0.55% | 买入期权 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $160043538 | 677519 | 0.52% | 股份 |
| Swiss National Bank | $157644816 | 663600 | 0.51% | 股份 |
| JANE STREET GROUP, LLC | $153701320 | 647000 | 0.50% | 卖出期权 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $141722832 | 596577 | 0.46% | 股份 |
| 1832 Asset Management L.P. | $139039117 | 585280 | 0.45% | 股份 |
| Sumitomo Mitsui Trust Group, Inc. | $132703867 | 558612 | 0.43% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $130681756 | 550100 | 0.42% | 股份 |
| BANK OF AMERICA CORP /DE/ | $126454568 | 532306 | 0.41% | 股份 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $123081499 | 518107 | 0.40% | 股份 |
| Vanguard Global Advisers, LLC | $122136010 | 514127 | 0.39% | 股份 |
| LPL Financial LLC | $120559117 | 507489 | 0.39% | 股份 |
| RHUMBLINE ADVISERS | $116899342 | 492084 | 0.38% | 股份 |
| UBS Group AG | $116739360 | 491410 | 0.38% | 股份 |
| National Pension Service | $113432762 | 477491 | 0.37% | 股份 |
| FRED ALGER MANAGEMENT, LLC | $111665316 | 470051 | 0.36% | 股份 |
| SEI INVESTMENTS CO | $110593700 | 465540 | 0.36% | 股份 |
| VANGUARD ASSET MANAGEMENT, Ltd | $109533215 | 461076 | 0.35% | 股份 |
| BARCLAYS PLC | $108067946 | 454908 | 0.35% | 股份 |
| LAZARD ASSET MANAGEMENT LLC | $106528318 | 448427 | 0.34% | 股份 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $104481026 | 439809 | 0.34% | 股份 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $104081450 | 438127 | 0.34% | 股份 |
| California Public Employees Retirement System | $103583999 | 436033 | 0.33% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $101984508 | 429300 | 0.33% | 买入期权 |
| TWO SIGMA ADVISERS, LP | $96441150 | 469300 | 0.31% | 股份 |
| JANUS HENDERSON GROUP PLC | $96030102 | 454526 | 0.31% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $95040000 | 400069 | 0.31% | 股份 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $94526074 | 397904 | 0.30% | 股份 |
| ING GROEP NV | $90805885 | 382244 | 0.29% | 股份 |
| Retirement Systems of Alabama | $89453931 | 376553 | 0.29% | 股份 |
| BANK OF NOVA SCOTIA | $88870008 | 374095 | 0.29% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $88654749 | 373189 | 0.29% | 股份 |
| Artemis Investment Management LLP | $87745162 | 369360 | 0.28% | 股份 |
| TD Asset Management Inc | $85393555 | 359461 | 0.28% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $85236528 | 358800 | 0.27% | 卖出期权 |
| Delta Accumulation, LLC | $81886932 | 344700 | 0.26% | 卖出期权 |
| STOREBRAND ASSET MANAGEMENT AS | $80500769 | 338865 | 0.26% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $79269258 | 333681 | 0.26% | 股份 |
| ROYAL BANK OF CANADA | $79026000 | 332656 | 0.25% | 股份 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $78334941 | 370711 | 0.25% | 股份 |
| Ensign Peak Advisors, Inc | $78327333 | 329716 | 0.25% | 股份 |
| GFS Advisors, LLC | $76777103 | 55 | 0.25% | 股份 |
| Integral Health Asset Management, LLC | $71268000 | 300000 | 0.23% | 股份 |
| Focus Partners Wealth | $69563786 | 292826 | 0.22% | 股份 |
| ZACKS INVESTMENT MANAGEMENT | $69526717 | 292669 | 0.22% | 股份 |
| PRUDENTIAL FINANCIAL INC | $69141838 | 291050 | 0.22% | 股份 |
| FIRST TRUST ADVISORS LP | $63253014 | 266262 | 0.20% | 股份 |
| Caisse de depot et placement du Quebec | $63072655 | 265502 | 0.20% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $60514609 | 254734 | 0.20% | 股份 |
| CANADA PENSION PLAN INVESTMENT BOARD | $60313158 | 253886 | 0.19% | 股份 |
| Gotham Asset Management, LLC | $59744915 | 251494 | 0.19% | 股份 |
| NATIXIS | $57996711 | 244135 | 0.19% | 股份 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57683884 | 243678 | 0.19% | 股份 |
| AMERIPRISE FINANCIAL INC | $56823880 | 239198 | 0.18% | 股份 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $56038504 | 235892 | 0.18% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $55998840 | 265008 | 0.18% | 股份 |
| Vest Financial, LLC | $55494016 | 233600 | 0.18% | 股份 |
| AVIVA PLC | $54653054 | 230060 | 0.18% | 股份 |
| COOKSON PEIRCE & CO INC | $54112422 | 227784 | 0.17% | 股份 |
| APG Asset Management N.V. | $52132088 | 250895 | 0.17% | 股份 |
| Delta Accumulation, LLC | $50101404 | 210900 | 0.16% | 买入期权 |
| Quantinno Capital Management LP | $49716731 | 209280 | 0.16% | 股份 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $48954227 | 206071 | 0.16% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $48870606 | 205719 | 0.16% | 股份 |
| Zurich Insurance Group Ltd/FI | $47315063 | 199171 | 0.15% | 股份 |
| CRAWFORD INVESTMENT COUNSEL INC | $45812739 | 192847 | 0.15% | 股份 |
| Cetera Investment Advisers | $45437576 | 191268 | 0.15% | 股份 |
| Empyrean Capital Partners, LP | $43758552 | 184200 | 0.14% | 股份 |
| Squarepoint Ops LLC | $43560427 | 183366 | 0.14% | 股份 |
| PFA Pension, Forsikringsaktieselskab | $43480161 | 183028 | 0.14% | 股份 |
| Davidson Kempner Capital Management LP | $43260389 | 182103 | 0.14% | 股份 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | $42795484 | 180146 | 0.14% | 股份 |
| Pictet Asset Management Holding SA | $42685837 | 179688 | 0.14% | 股份 |
| OSAIC HOLDINGS, INC. | $41443725 | 174339 | 0.13% | 股份 |
| CHURCHILL MANAGEMENT Corp | $40806561 | 242896 | 0.13% | 股份 |
| JONES FINANCIAL COMPANIES LLLP | $40701876 | 171074 | 0.13% | 股份 |
| AMF Tjanstepension AB | $40543890 | 170668 | 0.13% | 股份 |
| Voleon Capital Management LP | $40128160 | 168918 | 0.13% | 股份 |
| CITADEL ADVISORS LLC | $40028860 | 168500 | 0.13% | 买入期权 |
公司内部人士 85 位内幕人士 · 45 位高管 · 37 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Deborah Weitzman | CEO, PSS Segment | 2026年8月15日 F | 85255 | 0 | 1 | $-3216375 |
| Stephen M Mason | CEO, GMPD Segment | 2026年8月15日 F | 53061 | 0 | 0 | $0 |
| Jason M. Hollar | Chief Executive Officer | 2026年8月15日 F | 315132 | 0 | 2 | $-5386567 |
| Michael C Kaufmann | CEO | 2022年8月15日 M | 601065 | 0 | 0 | $0 |
| Victor L. Crawford | CEO, Pharmaceutical Segment | 2022年8月15日 F | 105699 | 0 | 0 | $0 |
| Jon L Giacomin | CEO, Medical Segment | 2019年8月15日 F | 61387 | 0 | 0 | $0 |
| Donald M Casey Jr. | CEO, Medical Segment | 2017年9月15日 F | 146503 | 0 | 0 | $0 |
| Michael A Lynch | CEO, Medical Segment | 2012年2月27日 M | 89204 | 0 | 0 | $0 |
| Kerry R Clark | Former Chairman and CEO | 2009年9月1日 A | 238635 | 0 | 0 | $0 |
| Mark W Parrish | CEO - HSCS | 2007年9月2日 F | 68041 | 0 | 0 | $0 |
| Ronald K Labrum | CEO-Supply Chain Svcs. | 2006年5月16日 M | 36082 | 0 | 0 | $0 |
| Joseph C Papa | Chmn & CEO, Pharm Techn & Svcs | 2004年12月13日 A | 14400 | 0 | 0 | $0 |
| Aaron E Alt | Chief Financial Officer | 2026年8月15日 F | 62495 | 0 | 0 | $0 |
| Jorge M Gomez | Chief Financial Officer | 2018年11月8日 F | 39582 | 0 | 0 | $0 |
| Jeffrey William Henderson | Chief Financial Officer | 2014年8月27日 M | 67190 | 0 | 0 | $0 |
| Richard J Miller | EVP & CFO | 2003年11月17日 A | — | 0 | 0 | $0 |
| George L Fotiades | President & COO | 2003年1月15日 P | 80278 | 0 | 0 | $0 |
| Valerie Christine Pitteroff | Chief Human Resources Officer | 2026年8月15日 F | 11757 | 0 | 0 | $0 |
| Mary C. Scherer | Chief Accounting Officer | 2026年8月15日 F | 5113 | 0 | 0 | $0 |
| Michelle D. Greene | Chief Information Officer | 2026年8月15日 F | 21980 | 0 | 0 | $0 |
| Jessica L Mayer | Chief Legal/Compliance Officer | 2026年8月15日 F | 62512 | 0 | 0 | $0 |
| Ola M Snow | Chief Human Resources Officer | 2025年8月19日 S | 15431 | 0 | 0 | $0 |
| Patricia M English | Chief Accounting Officer | 2022年8月15日 F | 9000 | 0 | 0 | $0 |
| Brian S Rice | Chief Information Officer | 2022年8月15日 F | 37850 | 0 | 0 | $0 |
| Michele Holcomb | EVP - Strategy & Corp. Dev. | 2022年8月15日 F | 44491 | 0 | 0 | $0 |
| Stuart G Laws | SVP & Chief Accounting Officer | 2020年8月15日 F | 12289 | 0 | 0 | $0 |
| Craig S Morford | Chief Legal/Compliance Officer | 2018年12月3日 F | 126301 | 0 | 0 | $0 |
| Patricia Morrison | Chief Information Officer | 2018年8月31日 F | 30725 | 0 | 0 | $0 |
| Pamela O. Kimmet | Chief Human Resources Officer | 2018年8月15日 F | 22612 | 0 | 0 | $0 |
| George S Barrett | Executive Chairman | 2018年8月15日 F | 502630 | 0 | 0 | $0 |
| Carole S Watkins | Chief HR Officer | 2016年5月20日 M | 31585 | 0 | 0 | $0 |
| Falk T Stephen | EVP, Gen. Counsel & Corp. Sec. | 2015年11月30日 G | 32455 | 0 | 0 | $0 |
| Meghan Fitzgerald | EVP, Strategy & Health Policy | 2015年11月17日 F | 16760 | 0 | 0 | $0 |
| Mark R Blake | EVP - Strategy & Corp. Dev. | 2014年11月7日 M | 20409 | 0 | 0 | $0 |
| Ivan K Fong | CLO & Secretary | 2008年11月1日 F | 50886 | 0 | 0 | $0 |
| Vivek Jain | EVP - Corp. Dev. & Strategy | 2008年9月26日 A | 39594 | 0 | 0 | $0 |
| Daniel J Walsh | EVP, Chf Ethcs & Compl Offcr | 2007年11月26日 I | 1740 | 0 | 0 | $0 |
| Eric Slusser | EVP, CAO & Controller | 2007年6月4日 M | 8573 | 0 | 0 | $0 |
| Brendan A Ford | EVP-Corporate Development | 2006年9月2日 F | 85978 | 0 | 0 | $0 |
| RUCCI ANTHONY J | EVP & Chief Admin. Officer | 2005年9月6日 G | 55382 | 0 | 0 | $0 |
| Gary D Dolch | EVP - Quality & Reg. Affairs | 2005年9月2日 A | 6137 | 0 | 0 | $0 |
| Jody R Davids | EVP & CIO | 2005年9月2日 A | 4607 | 0 | 0 | $0 |
| Paul S Williams | EVP, CLO & Secretary | 2005年2月17日 G | 7000 | 0 | 0 | $0 |
| Gary S Jensen | SVP - Corporate Controller | 2004年8月23日 A | 2462 | 0 | 0 | $0 |
| Stephen S Thomas | EVP-Group Pres.-AIS | 2004年2月24日 M | 31039 | 0 | 0 | $0 |
| Hall Patricia Hemingway | 董事 | 2026年4月15日 A | 28645 | 0 | 0 | $0 |
| Christine Mundkur | 董事 | 2025年11月5日 A | 7536 | 0 | 0 | $0 |
| Gregory B Kenny | 董事 | 2025年11月5日 A | 64194 | 0 | 0 | $0 |
| Sudhakar Ramakrishna | 董事 | 2025年3月15日 A | 1049 | 0 | 0 | $0 |
| Michelle Brennan | 董事 | 2024年11月6日 A | 7019 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Cardinal Health, Inc. ×2 申报 | 2014年6月5日 | — | 初始申报 | — | SEC |
| 未披露的报告人 | 2004年7月2日 | — | 初始申报 | — | SEC |
| 未披露的报告人 | 2004年5月28日 | — | 初始申报 | 并购/出售 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 222 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| EGGS · Tidal Trust III | 4.07% | 11627 NS | 2026年5月31日 | N-PORT |
| BCUS · Exchange Listed Funds Trust | 2.96% | 16250 NS | 2026年5月31日 | N-PORT |
| FXH · First Trust Exchange-Traded Alpha... | 1.98% | 89549 NS | 2026年4月30日 | N-PORT |
| NUMV · Nushares ETF Trust | 1.83% | 40961 NS | 2026年4月30日 | N-PORT |
| FLOW · Global X Funds | 1.70% | 2476 NS | 2026年5月31日 | N-PORT |
| ZECP · Zacks Trust | 1.69% | 29490 NS | 2026年5月31日 | N-PORT |
| COWZ · Pacer Funds Trust | 1.62% | 1528597 NS | 2026年4月30日 | N-PORT |
| QQWZ · Pacer Funds Trust | 1.62% | 3926 NS | 2026年4月30日 | N-PORT |
| NOBL · ProShares Trust | 1.41% | 791661 NS | 2026年5月31日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund ... | 1.38% | 796 NS | 2026年4月30日 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1.37% | 239259 NS | 2026年4月30日 | N-PORT |
| GROZ · Zacks Trust | 1.19% | 5456 NS | 2026年5月31日 | N-PORT |
| SRHQ · Elevation Series Trust | 1.09% | 10932 NS | 2026年4月30日 | N-PORT |
| NULV · Nushares ETF Trust | 1.03% | 110401 NS | 2026年4月30日 | N-PORT |
| AMOM · Exchange Listed Funds Trust | 1.00% | 1584 NS | 2026年4月30日 | N-PORT |
| ABFL · Abacus FCF ETF Trust | 0.80% | 20613 NS | 2026年4月30日 | N-PORT |
| ROE · EA Series Trust | 0.79% | 10387 NS | 2026年5月29日 | N-PORT |
| VAMO · Cambria ETF Trust | 0.78% | 3359 NS | 2026年4月30日 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.74% | 387 NS | 2026年5月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.74% | 109528 NS | 2026年4月30日 | N-PORT |
| UPSD · ETF Series Solutions | 0.73% | 3833 NS | 2026年4月30日 | N-PORT |
| LGDX · Tidal Trust III | 0.69% | 4947 NS | 2026年4月30日 | N-PORT |
| RXL · ProShares Trust | 0.67% | 2454 NS | 2026年5月31日 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.66% | 524 NS | 2026年4月30日 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.65% | 4692 NS | 2026年4月30日 | N-PORT |
| FTC · First Trust Exchange-Traded Alpha... | 0.58% | 38214 NS | 2026年4月30日 | N-PORT |
| QARP · DBX ETF Trust | 0.58% | 2209 NS | 2026年5月29日 | N-PORT |
| CLSE · Trust for Professional Managers | 0.58% | 18083 NS | 2026年5月31日 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0.56% | 2763 NS | 2026年5月31日 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.52% | 4667 NS | 2026年4月30日 | N-PORT |
| ITAN · EA Series Trust | 0.50% | 2246 NS | 2026年5月29日 | N-PORT |
| KRMA · Global X Funds | 0.47% | 2880 NS | 2026年5月31日 | N-PORT |
| JMID · Janus Detroit Street Trust | 0.45% | 423 NS | 2026年4月30日 | N-PORT |
| SFGV · EA Series Trust | 0.42% | 24321 NS | 2026年5月29日 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0.39% | 3776 NS | 2026年5月31日 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund ... | 0.38% | 3111 NS | 2026年5月31日 | N-PORT |
| SNPD · DBX ETF Trust | 0.38% | 50 NS | 2026年5月29日 | N-PORT |
| FEX · First Trust Exchange-Traded Alpha... | 0.37% | 29069 NS | 2026年4月30日 | N-PORT |
| RECS · Columbia ETF Trust I | 0.36% | 102127 NS | 2026年4月30日 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund ... | 0.36% | 11943 NS | 2026年5月31日 | N-PORT |
| LCOW · Pacer Funds Trust | 0.36% | 429 NS | 2026年4月30日 | N-PORT |
| REVS · Columbia ETF Trust I | 0.34% | 5059 NS | 2026年4月30日 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.34% | 10435 NS | 2026年4月30日 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 0.34% | 2104 NS | 2026年5月31日 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund ... | 0.34% | 7806 NS | 2026年4月30日 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund ... | 0.34% | 7680 NS | 2026年4月30日 | N-PORT |
| FTLS · First Trust Exchange-Traded Fund III | 0.34% | 40265 NS | 2026年4月30日 | N-PORT |
| PALC · Pacer Funds Trust | 0.33% | 3883 NS | 2026年4月30日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.29% | 7234 NS | 2026年4月30日 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund ... | 0.28% | 32009 NS | 2026年4月30日 | N-PORT |